Background: Glioma is the mostly occurred primary tumor in our central nervous system. As the chemotherapy and radiotherapy has failed to safely boost the efficacy of malignant glioma treatment during the last twenty years, there is an urgent need to find alternate new therapeutic protocols, and the immunological therapy is one of them. Dendritic cells (DCs) gained great attention in this field of research. Objective: To determine T lymphocytes (CTL) cytolytic activity, when stimulated by immunological product consisted of the fusion between glioma-DCs to be suggested as adjuvant in glioma therapy. Patients and method: This was a descriptive study conducted on 14 high grade glioma patients at Neurosurgery Department; Al-Maadi Military Hospital between 2018 and 2020. By using chemical fusion method, cultured glioma cells and DCs acquired from mononuclear cells of peripheral blood were fused. The processed glioma products were divided into 3 categories: (A) Suspension of fused glioma with CTL-effectors; (B) Suspension of co-culture glioma and DC cells with CTL-effectors, and (C) Lymphocytes only categorized as control. CTLs cytotoxicity effects on tumor cells were measured using MTT colorimetric analysis Ex-vivo. Results: Cytotoxic effects of CTLs activated by fused cells compared with co-cultured CTLs group and un-sensitized lymphocytes was shown to be significantly high. The potency level of CTLs fused category elevated tremendously (P-Value less than 0.01). Conclusion: The fusion method of dendritic cell based immune-therapy has highly potent antitumor effects via inducing CTLs actions.